Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04123379
Title Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.